Ignite Creation Date:
2025-12-24 @ 7:16 PM
Ignite Modification Date:
2025-12-25 @ 4:53 PM
Study NCT ID:
NCT04891003
Status:
UNKNOWN
Last Update Posted:
2021-05-18
First Post:
2021-05-12
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
The Identification of Optimal Ultrasonografic Tecniques for Determining the Location , Size and the Surgical Methods of Intestinal Endometriotric Nodules
Sponsor:
Zeynep Kamil Maternity and Pediatric Research and Training Hospital
Organization:
Study Overview
Official Title:
The Identification of Optimal Ultrasonografic Tecniques for Determining the Location , Size and the Surgical Methods of Intestinal Endometriotric Nodules
Status:
UNKNOWN
Status Verified Date:
2021-05
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Sonography
Brief Summary:
The identification of optimal ultrasonografic tecniques for determining the location , size and the surgical methods of intestinal endometriotric nodules
Detailed Description:
Nulliparous patients who had diagnosed with endometriosis ( endometrioma and/or deep endometriosis) without additional gynecological patology applying for routine gynecological check-up to Zeynep Kamil Training and Research Hospital, Gnecology and Obstetrics Clinic between March 2020 and March 2021 will be included in the study.Inclusion criteria in the study. Inclusion criterias are the presence of endometrioma and/or endometriosis diagnosed with ultrasonographic evaluation, nulliparity,no additional gynecological patology such as myoma uteri, polype, a history of pelvic inflammatuar disease, a history of cervical or uterine surgery, uterine anomalies as well as patients in the control group will be nulliparous and have no gynecological patology including endometrioma and/or endometriosis.All patients will be evaluated in the follicular phase.With the ultrasonographic examination, the uterine version ( anteversion or retroversion) will be evaluated, the length of the uterus (from fundus to cervix on the saggital axis), the anterior-posterior widest uterin length ( at the level of corpus uteri), the cervical length (the distance between the internal os and external os), the cervical anteroposterior length ath the internal os level and the servical canal length at the internal os level, uterocervical angle (the angle between the longitudinal axis of the cervix and the longitudinal axis of the uterine body will be measured three times consecutively , the avarage of the three measurements will be recoreded).with the 90 degree rotation of the probe at the transverse axis the width of the widest corpus level of uterus and the width of the cervix will be measured.Measurements will be made by the same clinician with the same ultrasound device. These measurements and the patients' age, BMI(body mass index), menarche cycle duration, dysmenorrhea, dyspareunia, family history in terms of endometriosis, endometrisosis stage will be recorded.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: